Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.

Related Articles
First Patient in Phase 1/2 Clinical Study of Gene Therapy is Treated for X-Linked RP Retina foundation showcases breakthroughs for treatment of age-related macular degeneration during eye on innovation conversation series Engaging iPad Game Approach as Alternative to Patching Recently@Retina Newsletter September 2023 Retina Foundation is Major Center for Next Phase of Gene Therapy for X-Linked Retinitis Pigmentosa: SKYLINE